ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1001

Long-Term Effectiveness and Cost Per Effectively Treated Patient With Biologics Used In Rheumatoid Arthritis

Vernon F. Schabert1, Jason Yeaw2, Jonathan Korn1, Caroleen Quach3, David J. Harrison4, Huifeng Yun5, George Joseph6, David H. Collier4 and Jeffrey R. Curtis7, 1IMS Health, Alexandria, VA, 2IMS Consulting Group, Alexandria, VA, 3Public Health Policy and Management, University of North Carolina at Chapel Hill, Gillings School of Public Health, Chapel Hill, NC, 4Amgen Inc., Thousand Oaks, CA, 5Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6Former Amgen Employee, Thousand Oaks, CA, 7Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologics, etanercept and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous work compared one-year cost per effectively treated patient with biologics for rheumatoid arthritis (RA) using a published, claims-based algorithm.1 Longer term comparisons are important since RA requires lifetime treatment. Using the same algorithm, treatment effectiveness (as a proxy for low disease activity or remission) and cost per effectively treated patient in the second year of biologic treatment for patients who met effectiveness criteria at the end of the first year was estimated. 

Methods:

Data were obtained from the IMS PharMetrics Plus™ database, comprising adjudicated medical and pharmaceutical claims for 150 million enrollees (40 million annually). The first-year cohort included patients with RA aged 18-63, initiating biologic treatment with etanercept, adalimumab, infliximab, or abatacept between Jan 1, 2007 and Dec 31, 2010, without diagnoses for other approved indications for these biologics or any biologic use for RA in the 6 months before initiation. Patients had to be continuously enrolled for 6 months before and 12 months after initiation; the subset of patients whose initial biologic was classified as “effective” by the algorithm and who were enrolled for a second year were included in this analysis. The algorithm defined lack of effectiveness as: medication possession ratio (MPR) <80% (or fewer infusions than specified on US label), increase in biologic dose or frequency, switching biologics, adding new non-biologic Disease Modifying Anti-Rheumatic Drugs, initiation or increase of glucocorticoid dose, or >1 parenteral or intra-articular injection. Cost was based on patient and health plan paid amounts for biologic drugs and drug administration from the claims.

Results:

Of 16,011 patients in the initial cohort, 1,999 met eligibility criteria for the second-year effectiveness analysis: etanercept (n=994), adalimumab (n=620), infliximab (n=229), and abatacept (n=156). Mean age was 50.8 (SD 8.9), 71.8% were female. In the second year, , 44.9% of abatacept,  47.4% of adalimumab, 47.2% of etanercept, and 45.4% of infliximab patients met criteria for effectiveness. Second-year cost per effectively treated patient as defined in the algorithm was $48,176 for abatacept, $37,082 for adalimumab, $37,306 for etanercept, and $36,954 for infliximab. From the prior study, comparable results were (31.0% and $50,141 etanercept, 28.6% and $56,941 adalimumab, 20.2% and $114,089 infliximab, 28.6% and $73,516 abatacept)1.

Conclusion: Despite similar effectiveness in the second year, cost per effectively treated patient was lower for TNF blockers (etanercept, adalimumab, and infliximab) than for abatacept.


Disclosure:

V. F. Schabert,
None;

J. Yeaw,

IMS Health,

5;

J. Korn,
None;

C. Quach,

Amgen, Inc.,

3;

D. J. Harrison,

Amgen Inc.,

1,

Amgen Inc.,

3;

H. Yun,
None;

G. Joseph,

Amgen Inc,

1,

Pfizer Inc,

1,

Sanofi-Aventis Pharmaceutical,

3;

D. H. Collier,

Amgen Inc.,

1,

Amgen Inc.,

3;

J. R. Curtis,

Roche/Genetech,

2,

UCB,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Corrona,

2,

Amgen,

2,

Pfizer Inc,

2,

BMS,

2,

Crescendo,

2,

AbbVie,

2,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-effectiveness-and-cost-per-effectively-treated-patient-with-biologics-used-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies